Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
London musician with brain tumour inspires Brighton triathlon fundraiser
Tuesday 26 August, 2025 A talented musician from London, who died from…
Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment
Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for…
A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care
RIYADH, Saudi Arabia, Aug. 24, 2025 (GLOBE NEWSWIRE) -- In a rare…
Seegene Unveils CURECA and STAgora at ADLM 2025, Advancing the Next Stage of Diagnostics
Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, highlights progress toward fully…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS
Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)
Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters…
Scaling Self-Care Can Be a Game-Changer in Global Fight Against Non-Communicable Diseases
Ahead of the upcoming UN General Assembly to set a new vision…
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test…